The interplay between ET-1 signaling and mTOR under hyperglycemic conditions in cardiomyocytes needs to be further investigated to unveil potential drug targets to treat diabetic cardiomyopathies. This evidence concerns the gene MTOR and diabetic cardiomyopathy.